Clinical Trial Update: Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS [Phase 2]

View source ↗

Summary

This update reports the completion and results posting of a Phase 2 double-blind, randomized trial evaluating mesenchymal stem cells for COVID-19–related acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Cristina Avendaño Solá | Conditions: Acute Respiratory Distress Syndrome, COVID-19 Pneumonia | Phase 2 | Status: COMPLETED | Results posted: 2026-03-17